Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy

Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients

(2018) Silvana Anna Maria Urru et al.   BMC CANCER

Clinicopathologic features and prognoses of different histologic types of triple-negative breast cancer: A large population-based analysis

(2018) Shen Zhao et al.   EJSO

Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis

(2018) Matthew N. Mills et al.   EUROPEAN JOURNAL OF CANCER

The Clinicopathological Features and Survival Outcomes of Different Histological Subtypes in Triple-negative Breast Cancer

(2018) Hong-Ye Liao et al.   Journal of Cancer

Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype

(2017) W. Fraser Symmans et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor

(2016) Brandon S. Sheffield et al.   BREAST CANCER RESEARCH AND TREATMENT

Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts

(2016) Priyanka Sharma et al.   CLINICAL CANCER RESEARCH

Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

(2016) Hope S. Rugo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

(2016) Brian D. Lehmann et al.   PLoS One

Preoperative Carboplatin–Paclitaxel–Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study

(2015) Valentina Guarneri et al.   ANNALS OF SURGICAL ONCOLOGY

Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer

(2015) Daniel G. Stover et al.   BREAST

Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer

(2015) C. Hatzis et al.   CLINICAL CANCER RESEARCH

New treatment strategies for patients with triple-negative breast cancer

(2015) Cornelia Liedtke et al.   CURRENT OPINION IN OBSTETRICS & GYNECOLOGY

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

(2015) William M. Sikov et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial

(2015) Harry D Bear et al.   LANCET ONCOLOGY

Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy

(2015) Florentia Peintinger et al.   MODERN PATHOLOGY

Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group

(2015) Elena Provenzano et al.   MODERN PATHOLOGY

Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression

(2014) Masashi Ando et al.   BREAST CANCER RESEARCH AND TREATMENT

Subtyping of triple-negative breast cancer: Implications for therapy

(2014) Vandana G. Abramson et al.   CANCER

Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

(2014) M. D. Burstein et al.   CLINICAL CANCER RESEARCH

Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies

(2014) Alfredo Berruti et al.   JOURNAL OF CLINICAL ONCOLOGY

Maastricht Delphi Consensus on Event Definitions for Classification of Recurrence in Breast Cancer Research

(2014) Martine Moossdorff et al.   JNCI-Journal of the National Cancer Institute

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

(2014) Patricia Cortazar et al.   LANCET

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

(2014) Gunter von Minckwitz et al.   LANCET ONCOLOGY

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)

(2013) B. Gerber et al.   ANNALS OF ONCOLOGY

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers

(2013) E H Lips et al.   BRITISH JOURNAL OF CANCER

Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

(2013) H. Masuda et al.   CLINICAL CANCER RESEARCH

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes

(2013) Brian D Lehmann et al.   JOURNAL OF PATHOLOGY

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

(2013) David Cameron et al.   LANCET ONCOLOGY

Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first-line treatment of metastatic triple-negative breast cancer†

(2012) Y. Fan et al.   ANNALS OF ONCOLOGY

A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study

(2012) E. Alba et al.   BREAST CANCER RESEARCH AND TREATMENT

Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry

(2012) Takayuki Iwamoto et al.   JOURNAL OF CLINICAL ONCOLOGY

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

(2012) Sohrab P. Shah et al.   NATURE

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Triple-Negative Breast Cancer Is Not a Contraindication for Breast Conservation

(2011) Farrell C. Adkins et al.   ANNALS OF SURGICAL ONCOLOGY

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Nodal Status and Clinical Outcomes in a Large Cohort of Patients With Triple-Negative Breast Cancer

(2011) Leonel F. Hernandez-Aya et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased Risk of Locoregional Recurrence for Women With T1-2N0 Triple-Negative Breast Cancer Treated With Modified Radical Mastectomy Without Adjuvant Radiation Therapy Compared With Breast-Conserving Therapy

(2011) Bassam S. Abdulkarim et al.   JOURNAL OF CLINICAL ONCOLOGY

Triple Negative Breast Cancer: Outcome Correlation With Immunohistochemical Detection of Basal Markers

(2010) Aye Aye Thike et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment

(2010) Helena R. Chang et al.   CANCER

Breast Cancer Subtypes and the Risk of Local and Regional Relapse

(2010) K. David Voduc et al.   JOURNAL OF CLINICAL ONCOLOGY

Metastatic Behavior of Breast Cancer Subtypes

(2010) Hagen Kennecke et al.   JOURNAL OF CLINICAL ONCOLOGY

Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists

(2010) Sunil Badve et al.   MODERN PATHOLOGY

Triple-Negative Breast Cancer

(2010) William D. Foulkes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pattern of metastatic spread in triple-negative breast cancer

(2008) Rebecca Dent et al.   BREAST CANCER RESEARCH AND TREATMENT

Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status

(2008) William D. Foulkes et al.   BREAST CANCER RESEARCH AND TREATMENT

Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

(2008) M. C.U. Cheang et al.   CLINICAL CANCER RESEARCH

Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27

(2008) Priya Rastogi et al.   JOURNAL OF CLINICAL ONCOLOGY

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

(2008) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY